TOKYO — Japan’s Eisai and American partner Biogen will transfer some production of active ingredients for their Alzheimer’s disease treatment lecanemab to the U.S. amid concerns that President Donald Trump will slap tariffs on pharmaceuticals.
Lecanemab was approved in the U.S. in 2023 as the world’s first drug to slow the cognitive decline associated with Alzheimer’s. The treatment also has received approval in Japan, China, Europe and elsewhere, with its use spreading gradually.
